source
- Gilead’s emvistegrast shows superior response to placebo in Phase 2 ulcerative colitis trialGilead Sciences reported that its investigational oral drug emvistegrast achieved a higher clinical response rate than placebo in a Phase 2 study of ulcerative colitis. The trial enrolled 238 patie…
- Astellas teams up with Boston miniprotein startup to explore AI-designed tiny proteinsAstellas Pharma announced a partnership with a Boston-based startup that specializes in miniproteins, small engineered proteins that can serve as therapeutic agents. The startup leverages artifici…